Pregabalin in the Treatment of Pain Due to Diabetic Peripheral Neuropathy
Status:
Completed
Trial end date:
2005-10-01
Target enrollment:
Participant gender:
Summary
The purposes of this study are to: 1) find out if pregabalin relieves pain in subjects with
painful diabetic peripheral neuropathy; 2) find out if pregabalin is safe at a dose of 600
mg/day (taken twice a day); and 3) find out if changes in nerve function happen during the
study.
Phase:
Phase 4
Details
Lead Sponsor:
Pfizer Pfizer's Upjohn has merged with Mylan to form Viatris Inc.